13F Holdings
中文EN

BIOA BioAge Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1709941 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.3%
TTM net income YoY-42.2%
TTM EPS YoY-118.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,401.8%
Net margin-1,253.6%
FCF margin-1,197.8%
EBITDA margin—

Returns

ROE-34.6%
ROA-32.0%
ROIC (approx.)-52.9%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets5.8%
Debt / equity0.00x
Current ratio15.51x
Interest coverage-913.20x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$8.99M$0—
R&D expense$73.97M$59.04M$33.89M
SG&A expense$27.81M$19.16M$14.51M
Operating income-$92.78M-$78.19M-$48.40M
Interest expense$697,000$2.37M$7.79M
Pretax income-$80.61M-$71.11M-$63.85M
Income tax$0$0$0
Net income-$80.61M-$71.11M-$63.85M
EBITDA-$92.58M-$77.99M-$48.20M
EPS (basic)-2.24-6.63-38.17
EPS (diluted)-2.24-6.63-38.17
Weighted avg. shares (diluted)35.93M10.73M1.67M
Balance sheet
Cash & equivalents$188.89M$354.35M$21.64M
Short-term investments$92.21M$0—
Receivables$769,000$0—
Current assets$286.79M$357.10M$25.31M
PP&E, net$963,000$591,000$323,000
Total assets$294.89M$358.23M$25.92M
Current liabilities$20.14M$27.77M$58.17M
Short-term debt$2.65M$6.00M$6.00M
Long-term debt$0$2.50M$8.20M
Total debt$2.65M$8.50M$14.20M
Total liabilities$22.84M$35.11M$66.60M
Shareholders' equity$272.05M$323.13M-$173.40M
Net debt-$186.24M-$345.85M-$7.44M
Shares outstanding37.39M35.85M1.67M
Cash flow statement
Operating cash flow-$81.63M-$51.52M-$37.36M
Capital expenditure$719,000$366,000$166,000
Free cash flow-$82.35M-$51.89M-$37.53M
Investing cash flow-$95.22M-$366,000-$266,000
Financing cash flow$11.47M$381.20M$34.94M
Depreciation & amortization$200,000$200,000$200,000
Stock-based compensation$11.69M$6.98M$3.02M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.